News
Kymriah is approved in Japan to treatrelapsed or refractory follicular lymphoma
Novartis Pharma announced that its CAR-T cell therapy Kymriah (tisagenlecleucel) has obtained an additional indication of relapsed or refractory follicular lymphoma in Japan
The approval is based on data from a global pivotal PII study, ELARA, which investigated the product in patients with relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. In the trial, 94 patients were evaluable for efficacy, with 69% of them achieving complete responses to meet the primary endpoint of the study.
Condition: Follicular Lymphoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.